Lung Cancer

FDA Approves Frontline Nivolumab/Ipilimumab/Chemo for Advanced NSCLC

May 26, 2020

Nivolumab plus ipilimumab in combination with chemotherapy was granted approval for the frontline treatment of patients with metastatic or recurrent non–small cell lung cancer who do not harbor EGFR or ALK genomic tumor abberations.

Sabari Examines Frontline and Second-Line Treatment Options in NSCLC

May 24, 2020

Joshua K. Sabari, MD, goes through treatment options in the frontline and second-line for patients with non–small cell lung cancer in a Targeted Oncology case-based peer perspectives live discussion.

Neoadjuvant Atezolizumab With Chemotherapy Feasible in Advanced NSCLC

May 24, 2020

"Our trial, together with ongoing randomized trials, provides more evidence on the risks and benefits of immunotherapy as a neoadjuvant treatment, and could help to answer questions regarding the optimal duration, best surrogate endpoint, and best predictive biomarkers for treatment."

Gerber Addresses the Role of Mutations and Treatment in NSCLC at Different Stages

May 23, 2020

In a Targeted Oncology case-based peer perspectives live discussion, David Gerber, MD, addresses the role of biomarkers in guiding treatment decisions for patients with non–small cell lung cancer based on a patient scenario.

FDA Approves Brigatinib as Frontline Treatment of ALK-Positive Metastatic NSCLC

May 22, 2020

The FDA has granted approval to brigatinib for the frontline treatment of patients with ALK-positive metastatic non–small cell lung cancer, as detected by an FDA-approved test.

FDA Approves Atezolizumab Monotherapy in Advanced PD-L1-High NSCLC

May 18, 2020

Atezolizumab has received its fifth indication in NSCLC as treatment of adult patients with metastatic non–small cell lung cancer who have high PD-L1 expression.

BMI May Stratify Clinical Trials to Measure Survival With Immunotherapy in NSCLC

May 18, 2020

A study found correlation between body mass index in patients with non–small cell lung cancer treated with atezolizumab and improved survival outcomes.

FDA Grants Breakthrough Designation to Trastuzumab Deruxtecan for HER2+ mNSCLC

May 18, 2020

"Today’s news is very welcome as we continue to evaluate the potential of Enhertu to help patients with this devastating type of lung cancer. Targeted treatments and immunotherapies are demonstrating tremendous advancements, but there remains an unmet medical need for patients with HER2 mutations who are not benefiting from such therapies or for those whose cancer continues to progress."

FDA Approves Nivolumab/Ipilimumab Combo for Advanced PD-L1+ NSCLC

May 15, 2020

The combination of the combination of nivolumab and ipilimumab is now approved by the FDA for the treatment of metastatic or recurrent non–small cell lung cancer with PD-L1 expression greater than 1%...

I/O Agent Demonstrates Lasting Clinical Benefit With or Without Pembrolizumab in Frontline NSCLC

May 14, 2020

"...These results leave us increasingly confident that ADXS-503 has the potential to restore or enhance sensitivity to checkpoint inhibitors..."